Wasatch Advisors’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-65,482
| Closed | -$1.6M | – | 319 |
|
|
2017
Q4 | $1.6M | Sell |
65,482
-157,591
| -71% | -$3.03M | 0.02% | 238 |
|
|
2017
Q3 | $4.12M | Sell |
223,073
-8,583
| -4% | -$149K | 0.06% | 174 |
|
|
2017
Q2 | $3.84M | Buy |
231,656
+14,462
| +7% | +$201K | 0.05% | 180 |
|
|
2017
Q1 | $3M | Buy |
217,194
+17,477
| +9% | +$281K | 0.04% | 220 |
|
|
2016
Q4 | $3.79M | Sell |
199,717
-14
| -0% | -$269 | 0.06% | 196 |
|
|
2016
Q3 | $4.43M | Buy |
199,731
+18,150
| +10% | +$341K | 0.07% | 200 |
|
|
2016
Q2 | $3.32M | Buy |
181,581
+40,024
| +28% | +$689K | 0.05% | 225 |
|
|
2016
Q1 | $2.47M | Buy |
141,557
+45
| +0% | +$728 | 0.04% | 241 |
|
|
2015
Q4 | $2.39M | Buy |
141,512
+27,766
| +24% | +$472K | 0.03% | 260 |
|
|
2015
Q3 | $2.05M | Buy |
113,746
+17,169
| +18% | +$382K | 0.03% | 282 |
|
|
2015
Q2 | $2.5M | Buy |
96,577
+18,577
| +24% | +$470K | 0.03% | 291 |
|
|
2015
Q1 | $1.71M | Buy |
+78,000
| New | +$1.68M | 0.02% | 306 |
|
Wasatch Advisors's ENTL Position: Q1 2018 in Review
Wasatch Advisors sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 65,482 shares — an estimated $1.6M sold.
Wasatch Advisors first reported a position in ENTL in Q1 2015 and held it in 12 quarters. The position peaked at $4.43M in Q3 2016. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.
- Wasatch Advisors reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
- Wasatch Advisors sold 65,482 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $1.6M.
- Wasatch Advisors first reported a position in Entellus Medical, Inc. Common Stock in Q1 2015 and held it in 12 quarters.
- Wasatch Advisors's Entellus Medical, Inc. Common Stock position peaked at $4.43M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.
Based on Wasatch Advisors's 13F filing for Q1 2018, filed 2 May 2018.